The Emerging Role of Cytokines in the Treatment of Advanced Melanoma

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

1998 • 437 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

1998 • 366 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen

1992 • 241 citations

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1998 • 206 citations

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

1990 • 206 citations

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 • 200 citations

Cutaneous melanoma: Prognosis and treatment results worldwide

1992 • 186 citations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

1993 • 181 citations

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α

1996 • 176 citations

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1996 • 176 citations

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

1994 • 153 citations

Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells.

1984 • 142 citations

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

1993 • 134 citations

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

1994 • 131 citations

Current therapy for malignant melanoma.

1989 • 127 citations

Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.

1993 • 121 citations

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma

1980 • 102 citations

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

1991 • 93 citations

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

1995 • 89 citations

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma

1998 • 88 citations

Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma

1996 • 72 citations

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1993 • 72 citations

Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial

1990 • 71 citations

Studies of interferons in the therapy of melanoma.

1991 • 67 citations

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma

1990 • 63 citations

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

1990 • 61 citations

Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group Study

1991 • 52 citations

A multicenter phase II clinical trial using dacarbazine and continuous infusion lnterleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

1995 • 47 citations

Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.

1994 • 46 citations

Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

1991 • 34 citations

A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma

1996 • 31 citations

Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy

1996 • 26 citations

Sequential Dacarbazine/Cisplatin and Interleukin-2 in Metastatic Melanoma

1991 • 24 citations

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

1996 • 24 citations

IFN-treatment of B16-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread

1988 • 21 citations

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.

1989 • 20 citations

Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: A phase I/II study

1989 • 9 citations

Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma

1996 • 2 citations

A randomized trial of IFN??/IL-2 with or without CDDP in advanced melanoma

1997 • 2 citations